Clinical trials: Gardasil Vaccine
Human Papillomavirus Infection
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human papilloma virus (HPV) is the most common viral infection of the reproductive system and is spread through contact with infected genital skin, mucous membranes, or bodily fluids.
- Trial name
- NCT07888686
- Testing
- 10vHPV, Gardasil9
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasia, Cervical Cancer
Impact of HPV Vaccine On The Prevalence Of HPV In Norway
The overall aim of the study is to assess the effect of school-based Human Papillomavirus (HPV) vaccination by comparing type-specific HPV prevalence between vaccinated and non-vaccinated women born in 1997.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Oropharyngeal Cancer
- Trial name
- NCT02934724
- Testing
- Self sample from vagina, Self sample from the oral cavity, Questionnaire
- Where
- Norway
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Cervical High Grade Squamous Intraepithelial Lesion
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL
Cervical cancer occurs commonly in HIV-infected women in South Africa. These women have poor response to treatment of cervical cancer precursors.
- Trial name
- NCT01928225
- Testing
- Human Papillomavirus vaccine
- Volunteers
- 180 people
- Sponsor
- University of Witwatersrand, South Africa
HPV Infections
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.
- Trial name
- HPV CSP01 (NCT00956553)
- Testing
- Cervarix, Gardasil
- Where
- 3 sites in United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Public Health England
Human Papilloma Virus, HPV
Acceptance of Human Papillomavirus Vaccination in Postpartum Women
Worldwide cervical cancer remains a major cause mortality among women. It is estimated that each year over 490,000 women are diagnosed with cervical cancer and more than 270,000 die from the disease.
- Conditions
- Human Papilloma Virus, HPV, Post Partum
- Trial name
- HPV Acceptance (NCT00730704)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Columbia University
Chronic Kidney Disease
Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease
People with chronic kidney disease are known to have immune response abnormalities, including a diminished response to some vaccinations.
- Trial name
- NCT00806676
- Testing
- Gardasil® Vaccine (FDA-approved vaccination regimen)
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- Johns Hopkins University
Human Papillomavirus
KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)
The Global Alliance to Immunize Against AIDS Vaccine Foundation (GAIA Vaccine Foundation or GAIA VF) proposes to carry out a Knowledge, Attitudes, and Practices (KAP) study in conjunction with a Willingness To Participate (WTP)…
- Trial name
- HPV (NCT01314404)
- Where
- 2 sites in Mali
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Global Alliance to Immunize Against AIDS Vaccine Foundation
Human Papillomavirus Vaccines
Immunogenicity and Safety of One Dose of HPV Vaccine
This study will assess the immunogenicity and safety of one dose of Cecolin and one dose of Gardasil
- Trial name
- NCT06345885
- Testing
- HPV vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Verruca Viral
Gardasil Versus Cervarix in the Treatment of Warts
Warts are common, benign, epidermal proliferations caused by HPV infecting skin and mucous membranes. Treatment of warts poses a true challenge despite existing variable therapeutic modalities, whether destructive or…
- Trial name
- NCT05383625
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Bivalent Human Papilloma Virus Vaccine, Saline
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Zagazig University
Gardasil Vaccine, Stem Cell Transplant
Gardasil Vaccination in Post Stem Cell Transplant Patients
Background: Gardasil , a recently approved vaccine for the sexually transmitted human papillomavirus (HPV), provides immunity to four types of HPV that are associated with genital warts and cervical, vaginal, and vulvar precancer…
- Conditions
- Gardasil Vaccine, Stem Cell Transplant, Immunogenicity
- Trial name
- NCT01092195
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Immunization, Efficacy
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it…
- Conditions
- Immunization, Efficacy, Human Papilloma Virus
- Trial name
- NCT03943875
- Testing
- 9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Neoplasms, Glandular and Epithelial, Diphtheria
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Data from this study are expected to demonstrate that V501 (Human Papillomavirus (HPV) [Types 6, 11, 16, 18] Recombinant Vaccine) , when administered concomitantly with a combined diphtheria, tetanus, pertussis (Tdap) vaccine and…
- Conditions
- Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough
- Trial name
- NCT00325130
- Testing
- Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine, Comparator: Menactra™ (Concomitant), Comparator: Adacel™ (Concomitant)
- Volunteers
- 1,042 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus
Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City
In the genital tract human papilloma virus (HPV), especially types 6 and 11 cause genital warts, the commonest viral sexually transmitted disease.
- Trial name
- NCT02382900
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine
- Where
- Mexico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
HPV, Cervical Cancer
Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)
This dose-ranging study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate that the vaccine is well-tolerated in women (2) To evaluate immune responses in women who are between 16 and 23…
- Conditions
- HPV, Cervical Cancer, Premalignancy Anogenital Warts
- Trial name
- NCT00260039
- Testing
- Comparator: Gardasil, Comparator: octavalent HPV Vaccine - dose formulation 1, Comparator: octavalent HPV Vaccine - dose formulation 2
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Post-Approval Safety Monitoring Program to Assess the Safety Profile of GARDASIL in China Usual Practice
This is a post-Approval Safety Monitoring Program to assess the safety profile of GARDASIL in china usual practice.
- Trial name
- NCT03659110
- Testing
- HPV 4
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Chaoyang District Centre for Disease Control and Prevention
Anogenital Human Papilloma Virus Infection, Condyloma Acuminata
Safety and Tolerability Study of V501 in Japanese Boys (V501-200)
This is a study of V501 [quadrivalent Human Papillomavirus (HPV) (Type 6, 11, 16 and 18) L1 virus-like particle (VLP) vaccine] in healthy Japanese boys. This study will consist of two periods.
- Trial name
- NCT02576054
- Testing
- V501
- Where
- Japan
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus Infection Type 16
Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination
The current study is an open-label, non-randomized, longitudinal exploratory trial using the licensed Gardasil 9 (9vHPV) vaccine in an off-label context to investigate biological and immunological outcomes in human papillomavirus…
- Trial name
- URVIVE (NCT07407569)
- Testing
- Gardasil 9 (2 dose regimen)
- Where
- 3 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- Universiteit Antwerpen
Sexual Transmission of Infection
Preparedness Study - HPV Vaccine
Moffitt Cancer Center is the Coordinating Center for this study. The purpose of this study is to develop and test the infrastructure to conduct a future Phase III vaccine efficacy trial to assess trial feasibility, and to assess…
- Trial name
- NCT01489527
- Testing
- Gardasil Vaccine
- Where
- 2 sites in United States, South Africa
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Human Papillomavirus Vaccines
Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9
This study will assess the immunogenicity of one dose of Gardasil and one dose of Gardasil-9
- Trial name
- NCT03431246
- Testing
- Gardasil and Gardasil-9
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laval University